MicroRNA-423 may regulate diabetic vasculopathy
To test the hypothesis that microRNAs may play a role in diabetic retinopathy, we measured the levels of different markers [microRNAs, vascular endothelial growth factor (VEGF), nitric oxide (NO), and total antioxidant capacity (TAO)] in patients with type 2 diabetes mellitus (T2DM) and microvascula...
Gespeichert in:
Veröffentlicht in: | Clinical and experimental medicine 2019-11, Vol.19 (4), p.469-477 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 477 |
---|---|
container_issue | 4 |
container_start_page | 469 |
container_title | Clinical and experimental medicine |
container_volume | 19 |
creator | Blum, Arnon Meerson, Ari Rohana, Hanan Jabaly, Hanin Nahul, Nahul Celesh, Dorina Romanenko, Olga Tamir, Snait |
description | To test the hypothesis that microRNAs may play a role in diabetic retinopathy, we measured the levels of different markers [microRNAs, vascular endothelial growth factor (VEGF), nitric oxide (NO), and total antioxidant capacity (TAO)] in patients with type 2 diabetes mellitus (T2DM) and microvascular complications. Sixty-nine patients were recruited: 22 healthy subjects, ten T2DM patients without retinopathy, 22 with nonproliferative diabetic retinopathy, and 15 with proliferative diabetic retinopathy (PDR). Serum levels of NO, VEGF, TAO and 16 candidate microRNAs were measured. Additionally, the mRNA levels of endothelial nitric oxide synthase (eNOS), induced NOS (iNOS), C reactive protein (CRP), VEGF, tumor necrosis factor α (TNFα), PON2, p22, and SOD2 were measured in human vascular endothelial cells cultured in the presence of pooled sera from the subject groups. Plasma miR-423 levels showed a significant ~ twofold decrease in patients with PDR compared to controls. P lasma NO levels were significantly higher in retinopathy, VEGF levels were significantly lower, and TAO was significantly decreased. eNOS mRNA levels were lower in the cells of T2DM patients without retinopathy, but higher in PDR. PON2, p22, and SOD2 mRNA levels were all significantly lower in PDR. CRP, TNFα, iNOS, and VEGF mRNA levels showed no significant association with disease status. Lowered miR-423 levels in diabetic patients showed a correlation with VEGF and an inverse correlation between NO and eNOS expression. Our findings suggest a cross talk between miR-423 and VEGF signaling, affecting eNOS function. miR-423 may be involved in the regulation of diabetic vascular retinal proliferation. |
doi_str_mv | 10.1007/s10238-019-00573-8 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2275952310</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275952310</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-7b6fdb208fb683244868f595f83ed4b5525963abd142eb8e47c447dd740fa9423</originalsourceid><addsrcrecordid>eNp9kM1LwzAchoMobk7_AQ9S8OIl7pevJj2O4RdMBdFzSNp0drTrTFph_73RTgUPkkMCeX5v3jwInRK4JAByGghQpjCQDAMIybDaQ2MiMoIzQdX-7qxUBiN0FMIKgAjF4BCNGOGUCpKO0fS-yn379DDDnLKkMdvEu2Vfm84lRWWs66o8eTch7-t2Y7rX7TE6KE0d3Mlun6CX66vn-S1ePN7czWcLnDMpOixtWhaWgiptqhjlXKWqFJkoFXMFt0JQkaXM2CIWcVY5LnPOZVFIDqXJYpUJuhhyN759613odFOF3NW1Wbu2D5pSGeMoIxDR8z_oqu39OrbTlEEqGIkrUnSg4ndD8K7UG181xm81Af2pUw86ddSpv3RqFYfOdtG9bVzxM_LtLwJsAEK8Wi-d_337n9gPMRJ81A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2306531313</pqid></control><display><type>article</type><title>MicroRNA-423 may regulate diabetic vasculopathy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Blum, Arnon ; Meerson, Ari ; Rohana, Hanan ; Jabaly, Hanin ; Nahul, Nahul ; Celesh, Dorina ; Romanenko, Olga ; Tamir, Snait</creator><creatorcontrib>Blum, Arnon ; Meerson, Ari ; Rohana, Hanan ; Jabaly, Hanin ; Nahul, Nahul ; Celesh, Dorina ; Romanenko, Olga ; Tamir, Snait</creatorcontrib><description>To test the hypothesis that microRNAs may play a role in diabetic retinopathy, we measured the levels of different markers [microRNAs, vascular endothelial growth factor (VEGF), nitric oxide (NO), and total antioxidant capacity (TAO)] in patients with type 2 diabetes mellitus (T2DM) and microvascular complications. Sixty-nine patients were recruited: 22 healthy subjects, ten T2DM patients without retinopathy, 22 with nonproliferative diabetic retinopathy, and 15 with proliferative diabetic retinopathy (PDR). Serum levels of NO, VEGF, TAO and 16 candidate microRNAs were measured. Additionally, the mRNA levels of endothelial nitric oxide synthase (eNOS), induced NOS (iNOS), C reactive protein (CRP), VEGF, tumor necrosis factor α (TNFα), PON2, p22, and SOD2 were measured in human vascular endothelial cells cultured in the presence of pooled sera from the subject groups. Plasma miR-423 levels showed a significant ~ twofold decrease in patients with PDR compared to controls. P lasma NO levels were significantly higher in retinopathy, VEGF levels were significantly lower, and TAO was significantly decreased. eNOS mRNA levels were lower in the cells of T2DM patients without retinopathy, but higher in PDR. PON2, p22, and SOD2 mRNA levels were all significantly lower in PDR. CRP, TNFα, iNOS, and VEGF mRNA levels showed no significant association with disease status. Lowered miR-423 levels in diabetic patients showed a correlation with VEGF and an inverse correlation between NO and eNOS expression. Our findings suggest a cross talk between miR-423 and VEGF signaling, affecting eNOS function. miR-423 may be involved in the regulation of diabetic vascular retinal proliferation.</description><identifier>ISSN: 1591-8890</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-019-00573-8</identifier><identifier>PMID: 31422516</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Aged ; Antioxidants ; C-reactive protein ; Case-Control Studies ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetic retinopathy ; Diabetic Retinopathy - blood ; Diabetic Retinopathy - genetics ; Down-Regulation ; Endothelial cells ; Female ; Genetic Predisposition to Disease ; Hematology ; Human Umbilical Vein Endothelial Cells ; Humans ; Internal Medicine ; Male ; Medicine ; Medicine & Public Health ; MicroRNAs ; MicroRNAs - blood ; Microvasculature ; Middle Aged ; miRNA ; mRNA ; Nitric oxide ; Nitric Oxide - blood ; Nitric Oxide Synthase Type III - blood ; Nitric Oxide Synthase Type III - genetics ; Nitric-oxide synthase ; Oncology ; Original Article ; Retina ; Retinopathy ; Serum levels ; Superoxide dismutase ; Tumor necrosis factor-α ; Vascular diseases ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - blood</subject><ispartof>Clinical and experimental medicine, 2019-11, Vol.19 (4), p.469-477</ispartof><rights>Springer Nature Switzerland AG 2019</rights><rights>Copyright Springer Nature B.V. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-7b6fdb208fb683244868f595f83ed4b5525963abd142eb8e47c447dd740fa9423</citedby><cites>FETCH-LOGICAL-c375t-7b6fdb208fb683244868f595f83ed4b5525963abd142eb8e47c447dd740fa9423</cites><orcidid>0000-0003-3863-4036</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10238-019-00573-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10238-019-00573-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31422516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Blum, Arnon</creatorcontrib><creatorcontrib>Meerson, Ari</creatorcontrib><creatorcontrib>Rohana, Hanan</creatorcontrib><creatorcontrib>Jabaly, Hanin</creatorcontrib><creatorcontrib>Nahul, Nahul</creatorcontrib><creatorcontrib>Celesh, Dorina</creatorcontrib><creatorcontrib>Romanenko, Olga</creatorcontrib><creatorcontrib>Tamir, Snait</creatorcontrib><title>MicroRNA-423 may regulate diabetic vasculopathy</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><addtitle>Clin Exp Med</addtitle><description>To test the hypothesis that microRNAs may play a role in diabetic retinopathy, we measured the levels of different markers [microRNAs, vascular endothelial growth factor (VEGF), nitric oxide (NO), and total antioxidant capacity (TAO)] in patients with type 2 diabetes mellitus (T2DM) and microvascular complications. Sixty-nine patients were recruited: 22 healthy subjects, ten T2DM patients without retinopathy, 22 with nonproliferative diabetic retinopathy, and 15 with proliferative diabetic retinopathy (PDR). Serum levels of NO, VEGF, TAO and 16 candidate microRNAs were measured. Additionally, the mRNA levels of endothelial nitric oxide synthase (eNOS), induced NOS (iNOS), C reactive protein (CRP), VEGF, tumor necrosis factor α (TNFα), PON2, p22, and SOD2 were measured in human vascular endothelial cells cultured in the presence of pooled sera from the subject groups. Plasma miR-423 levels showed a significant ~ twofold decrease in patients with PDR compared to controls. P lasma NO levels were significantly higher in retinopathy, VEGF levels were significantly lower, and TAO was significantly decreased. eNOS mRNA levels were lower in the cells of T2DM patients without retinopathy, but higher in PDR. PON2, p22, and SOD2 mRNA levels were all significantly lower in PDR. CRP, TNFα, iNOS, and VEGF mRNA levels showed no significant association with disease status. Lowered miR-423 levels in diabetic patients showed a correlation with VEGF and an inverse correlation between NO and eNOS expression. Our findings suggest a cross talk between miR-423 and VEGF signaling, affecting eNOS function. miR-423 may be involved in the regulation of diabetic vascular retinal proliferation.</description><subject>Adult</subject><subject>Aged</subject><subject>Antioxidants</subject><subject>C-reactive protein</subject><subject>Case-Control Studies</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetic retinopathy</subject><subject>Diabetic Retinopathy - blood</subject><subject>Diabetic Retinopathy - genetics</subject><subject>Down-Regulation</subject><subject>Endothelial cells</subject><subject>Female</subject><subject>Genetic Predisposition to Disease</subject><subject>Hematology</subject><subject>Human Umbilical Vein Endothelial Cells</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>MicroRNAs</subject><subject>MicroRNAs - blood</subject><subject>Microvasculature</subject><subject>Middle Aged</subject><subject>miRNA</subject><subject>mRNA</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - blood</subject><subject>Nitric Oxide Synthase Type III - blood</subject><subject>Nitric Oxide Synthase Type III - genetics</subject><subject>Nitric-oxide synthase</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Retina</subject><subject>Retinopathy</subject><subject>Serum levels</subject><subject>Superoxide dismutase</subject><subject>Tumor necrosis factor-α</subject><subject>Vascular diseases</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><issn>1591-8890</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1LwzAchoMobk7_AQ9S8OIl7pevJj2O4RdMBdFzSNp0drTrTFph_73RTgUPkkMCeX5v3jwInRK4JAByGghQpjCQDAMIybDaQ2MiMoIzQdX-7qxUBiN0FMIKgAjF4BCNGOGUCpKO0fS-yn379DDDnLKkMdvEu2Vfm84lRWWs66o8eTch7-t2Y7rX7TE6KE0d3Mlun6CX66vn-S1ePN7czWcLnDMpOixtWhaWgiptqhjlXKWqFJkoFXMFt0JQkaXM2CIWcVY5LnPOZVFIDqXJYpUJuhhyN759613odFOF3NW1Wbu2D5pSGeMoIxDR8z_oqu39OrbTlEEqGIkrUnSg4ndD8K7UG181xm81Af2pUw86ddSpv3RqFYfOdtG9bVzxM_LtLwJsAEK8Wi-d_337n9gPMRJ81A</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Blum, Arnon</creator><creator>Meerson, Ari</creator><creator>Rohana, Hanan</creator><creator>Jabaly, Hanin</creator><creator>Nahul, Nahul</creator><creator>Celesh, Dorina</creator><creator>Romanenko, Olga</creator><creator>Tamir, Snait</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3863-4036</orcidid></search><sort><creationdate>20191101</creationdate><title>MicroRNA-423 may regulate diabetic vasculopathy</title><author>Blum, Arnon ; Meerson, Ari ; Rohana, Hanan ; Jabaly, Hanin ; Nahul, Nahul ; Celesh, Dorina ; Romanenko, Olga ; Tamir, Snait</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-7b6fdb208fb683244868f595f83ed4b5525963abd142eb8e47c447dd740fa9423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antioxidants</topic><topic>C-reactive protein</topic><topic>Case-Control Studies</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetic retinopathy</topic><topic>Diabetic Retinopathy - blood</topic><topic>Diabetic Retinopathy - genetics</topic><topic>Down-Regulation</topic><topic>Endothelial cells</topic><topic>Female</topic><topic>Genetic Predisposition to Disease</topic><topic>Hematology</topic><topic>Human Umbilical Vein Endothelial Cells</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>MicroRNAs</topic><topic>MicroRNAs - blood</topic><topic>Microvasculature</topic><topic>Middle Aged</topic><topic>miRNA</topic><topic>mRNA</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - blood</topic><topic>Nitric Oxide Synthase Type III - blood</topic><topic>Nitric Oxide Synthase Type III - genetics</topic><topic>Nitric-oxide synthase</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Retina</topic><topic>Retinopathy</topic><topic>Serum levels</topic><topic>Superoxide dismutase</topic><topic>Tumor necrosis factor-α</topic><topic>Vascular diseases</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blum, Arnon</creatorcontrib><creatorcontrib>Meerson, Ari</creatorcontrib><creatorcontrib>Rohana, Hanan</creatorcontrib><creatorcontrib>Jabaly, Hanin</creatorcontrib><creatorcontrib>Nahul, Nahul</creatorcontrib><creatorcontrib>Celesh, Dorina</creatorcontrib><creatorcontrib>Romanenko, Olga</creatorcontrib><creatorcontrib>Tamir, Snait</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blum, Arnon</au><au>Meerson, Ari</au><au>Rohana, Hanan</au><au>Jabaly, Hanin</au><au>Nahul, Nahul</au><au>Celesh, Dorina</au><au>Romanenko, Olga</au><au>Tamir, Snait</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MicroRNA-423 may regulate diabetic vasculopathy</atitle><jtitle>Clinical and experimental medicine</jtitle><stitle>Clin Exp Med</stitle><addtitle>Clin Exp Med</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>19</volume><issue>4</issue><spage>469</spage><epage>477</epage><pages>469-477</pages><issn>1591-8890</issn><eissn>1591-9528</eissn><abstract>To test the hypothesis that microRNAs may play a role in diabetic retinopathy, we measured the levels of different markers [microRNAs, vascular endothelial growth factor (VEGF), nitric oxide (NO), and total antioxidant capacity (TAO)] in patients with type 2 diabetes mellitus (T2DM) and microvascular complications. Sixty-nine patients were recruited: 22 healthy subjects, ten T2DM patients without retinopathy, 22 with nonproliferative diabetic retinopathy, and 15 with proliferative diabetic retinopathy (PDR). Serum levels of NO, VEGF, TAO and 16 candidate microRNAs were measured. Additionally, the mRNA levels of endothelial nitric oxide synthase (eNOS), induced NOS (iNOS), C reactive protein (CRP), VEGF, tumor necrosis factor α (TNFα), PON2, p22, and SOD2 were measured in human vascular endothelial cells cultured in the presence of pooled sera from the subject groups. Plasma miR-423 levels showed a significant ~ twofold decrease in patients with PDR compared to controls. P lasma NO levels were significantly higher in retinopathy, VEGF levels were significantly lower, and TAO was significantly decreased. eNOS mRNA levels were lower in the cells of T2DM patients without retinopathy, but higher in PDR. PON2, p22, and SOD2 mRNA levels were all significantly lower in PDR. CRP, TNFα, iNOS, and VEGF mRNA levels showed no significant association with disease status. Lowered miR-423 levels in diabetic patients showed a correlation with VEGF and an inverse correlation between NO and eNOS expression. Our findings suggest a cross talk between miR-423 and VEGF signaling, affecting eNOS function. miR-423 may be involved in the regulation of diabetic vascular retinal proliferation.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>31422516</pmid><doi>10.1007/s10238-019-00573-8</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3863-4036</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1591-8890 |
ispartof | Clinical and experimental medicine, 2019-11, Vol.19 (4), p.469-477 |
issn | 1591-8890 1591-9528 |
language | eng |
recordid | cdi_proquest_miscellaneous_2275952310 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Adult Aged Antioxidants C-reactive protein Case-Control Studies Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetic retinopathy Diabetic Retinopathy - blood Diabetic Retinopathy - genetics Down-Regulation Endothelial cells Female Genetic Predisposition to Disease Hematology Human Umbilical Vein Endothelial Cells Humans Internal Medicine Male Medicine Medicine & Public Health MicroRNAs MicroRNAs - blood Microvasculature Middle Aged miRNA mRNA Nitric oxide Nitric Oxide - blood Nitric Oxide Synthase Type III - blood Nitric Oxide Synthase Type III - genetics Nitric-oxide synthase Oncology Original Article Retina Retinopathy Serum levels Superoxide dismutase Tumor necrosis factor-α Vascular diseases Vascular endothelial growth factor Vascular Endothelial Growth Factor A - blood |
title | MicroRNA-423 may regulate diabetic vasculopathy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A24%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MicroRNA-423%20may%20regulate%20diabetic%20vasculopathy&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Blum,%20Arnon&rft.date=2019-11-01&rft.volume=19&rft.issue=4&rft.spage=469&rft.epage=477&rft.pages=469-477&rft.issn=1591-8890&rft.eissn=1591-9528&rft_id=info:doi/10.1007/s10238-019-00573-8&rft_dat=%3Cproquest_cross%3E2275952310%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2306531313&rft_id=info:pmid/31422516&rfr_iscdi=true |